MDS Pharma Services Names New Site Director for Facility in Geneva
13 Februar 2004 - 10:00PM
PR Newswire (US)
MDS Pharma Services Names New Site Director for Facility in Geneva
MONTREAL, Canada, February 13 /PRNewswire/ -- Appointment Signals
Renewed Focus on CNS Pharmacology Services MDS Pharma Services, a
leading provider of innovative drug discovery and development
solutions, has promoted Claire Abadie, Ph.D., to site manager for
its Geneva, Switzerland, facility that offers CNS (Central Nervous
System) Pharmacology and in vitro Safety Pharmacology services.
"Dr. Abadie's promotion is akey element of the company's renewed
and expanded focus on providing CNS Pharmacology and in vitro
Safety Assessment services," said Gilbert Godin, group vice
president, Early Stage Development. "We are putting considerable
resources behind our effort to further develop and promote our
capabilities and services in these important areas of drug
discovery." The company offers non-GLP assays on in vivo models of
the following CNS diseases: stroke, epilepsy, Alzheimer's disease,
Parkinson's disease, Amyotrophic Lateral Sclerosis disease (also
known as Lou Gerhig's Disease), anxiety, depression and
schizophrenia. In addition, it offers in vitro Safety Pharmacology
services focused on electrophysiology, such as patch-clamp
evaluation of hERG potassium-channels in CHO cells and Action
Potential analysis on Purkinje fibers. Dr. Abadie has served as the
head of Cardiovascular Pharmacology and Electrophysiology in Geneva
since 1998, and as study director for MDS Pharma Services' hERG
patch-clamp assay cells since 2001. She earned her doctorate in
Physiology and Cardiovascular Pharmacology from the University of
Burgundy, Dijon, France. MDS Pharma Services offers a full spectrum
of resources to meet the drug discovery and development needs of
the pharmaceutical and biotechnology industries. With numerous
facilities strategically located around the world, the company
applies advanced scientific and technological expertise to each
stage of the drug discovery and development process - early stage:
lead optimisation, pre-IND research, pharmaceutical and
biopharmaceutical development, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis; and late stage:
global clinical development (phases IIb-IV) and central lab. For
more information, visit MDS Pharma Services' Web site at
www.mdsps.com . MDS Pharma Services is part of MDS Inc. (NYSE: MDZ;
Toronto: MDS) an international health and life sciences company. At
MDS Inc., our 10,000 highly skilled people provide services,
products and instruments enabling health sciences organizations to
enhance the well being of people around the world. We focus on
helping discover and test new drugs, assisting doctors to diagnose
and treat patients and preventing the spread of disease. Find out
more about MDS Inc. at www.mdsintl.com or by calling
+1-888-MDS-7222, 24 hours a day. Web site: http://www.mdsps.com
http://www.mdsintl.com DATASOURCE: MDS Pharma Services CONTACT:
Kevin Langin of MDS Pharma Services, +1-402-476-2811
Copyright
Mds (NYSE:MDZ)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Mds (NYSE:MDZ)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
Echtzeit-Nachrichten über Mds (New York Börse): 0 Nachrichtenartikel
Weitere Mds News-Artikel